Regencell Bioscience Holdings (RGC) Short term Debt (2020 - 2021)
Regencell Bioscience Holdings' (RGC) quarterly Short term Debt came in at $431969.0 in Q2 2021, down 85.93% YoY from $3.1 million in Q2 2020, and down 85.93% on a QoQ basis from $3.1 million in Q2 2020.
Regencell Bioscience Holdings (RGC) Short term Debt (2020 - 2021) Analysis & Trends
Regencell Bioscience Holdings (RGC) has 2 years of Short term Debt data on file, last reported at $431969.0 in Q2 2021.
- Quarterly Short term Debt fell 85.93% year-over-year to $431969.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $431969.0 (down 85.93% YoY) and the FY2021 annual result came in at $431969.0, down 85.93% from the prior year.
- Short term Debt slipped to $431969.0 in Q2 2021, from $3.1 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $3.1 million in Q2 2020 to a low of $431969.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Regencell Bioscience Holdings | 2.61 Bn | 2.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 431,969.00 |
| Jun 30, 2020 | 3.07 Mn |